Bajaj H, Ye C, Hanley AJ, Connelly PW, Sermer M, Zinman B, Retnakaran R. Prior lactation reduces future diabetic risk through sustained postweaning effects on insulin sensitivity. Breastfeeding for Ն12 mo is recommended for optimal infant nutrition but may hold maternal benefits as well. Indeed, lactation has been associated with lower long-term risk of diabetes in the mother, but the mechanism by which it imparts sustained postweaning effects on glucose tolerance remains unclear. In this context, we postulated that lactation could potentially induce postweaning beneficial effects on glucose tolerance by modifying the natural history of insulin sensitivity and/or pancreatic ␤-cell function over time. Thus, in this study, we evaluated the relationships between duration of lactation [Յ3 mo (n ϭ 70), 3-12 mo (n ϭ 140), and Ն12 mo (n ϭ 120)] and trajectories of insulin sensitivity/ resistance, ␤-cell function, and glycemia over the first 3 yr postpartum in a cohort of 330 women comprising the full spectrum of glucose tolerance in pregnancy, who underwent serial metabolic characterization, including oral glucose tolerance tests, at 3 mo, 1 yr, and 3 yr postpartum. The prevalence of dysglycemia (pre-diabetes/diabetes) at 3 yr postpartum was lower in women who breastfed for Ն12 mo (12.5%) than in those who breastfed for Յ3 mo (21.4%) or for 3-12 mo (25.7%)(overall P ϭ 0.028). On logistic regression analysis, lactation for Ն12 mo independently predicted a lower likelihood of prediabetes/diabetes at 3 yr postpartum (OR ϭ 0.37, 95% CI 0.18 -0.78, P ϭ 0.009). Notably, lactation for Ն12 mo predicted lesser worsening of insulin sensitivity/resistance (P Ͻ 0.0001), fasting glucose (P Ͻ 0.0001), and 2-h glucose (P ϭ 0.011) over 3 yr compared with lactation Յ3 mo but no differences in ␤-cell function (P Ն 0.37). It has thus emerged that adherence to current breastfeeding recommendations reduces future diabetic risk through sustained postweaning effects on insulin sensitivity/resistance but not ␤-cell function.
THE AMERICAN ACADEMY OF PEDIATRICS (AAP) recommends that women breastfeed their infant for at least 12 mo, with exclusive breastfeeding for the first 6 mo of life (1) . Although this recommendation is intended to optimize early-life nutrition for the child, it likely offers metabolic benefits for the mother also. Indeed, lactation has acute beneficial effects on maternal metabolism, including increased energy expenditure (for milk production), better lipid profile, lower blood glucose levels, and greater insulin sensitivity (2, 10, 24) . Importantly, epidemiological studies have found that middle-aged women who report a longer duration of lactation earlier in life have a lower long-term risk of type 2 diabetes (T2DM), although the mechanism underlying this relationship remains unclear (7, 20, 23, 25) . In younger women with recent gestational diabetes mellitus (GDM), a population known to be at high risk for postpartum progression to T2DM, lactation for Ͼ10 mo has been associated with a reduced incidence of T2DM at 2 yr postpartum (5) . Taken together, this literature suggests that the AAP breastfeeding recommendation may potentially hold glycemic benefits for the mother that persist after weaning.
However, there are currently three key limitations of this literature that preclude confirmation of the anticipated maternal benefit of the AAP recommendation. First, there has been limited direct demonstration of sustained postweaning effects on glucose homeostasis and its determinants after the cessation of breastfeeding (7, 14, 15) . This critical evidence could 1) link the established acute metabolic benefits of lactation with modification of future risk of diabetes and 2) provide insight into the likely mechanism underlying such a relationship. Second, such postweaning effects should ideally be evaluated in all postpartum women rather than just the high-risk subset of those with GDM (since the AAP recommendation applies to all women). Third, these effects need to be evaluated in relation to achievement of the AAP-recommended targets for breastfeeding (Ն12 mo, with Ն6 exclusive). Thus, we sought to address each of these limitations in the current study.
The main pathophysiological defects underlying T2DM and its precursor prediabetes are insulin resistance and pancreatic ␤-cell dysfunction (9) . In this context, we reasoned that lactation potentially could induce postweaning beneficial effects on glucose tolerance by modifying the natural history of insulin sensitivity and/or ␤-cell function over time. Specifically, we hypothesized that lactation exposure may favorably alter the trajectories of maternal metabolic function in the years there-after. Thus, our objective in this study was to prospectively evaluate the effect of lactation exposure in the first year on the trajectories of maternal insulin sensitivity/resistance, ␤-cell function, and glycemia over the first 3 yr postpartum in a cohort of women comprising the full spectrum of glucose tolerance in pregnancy (from normal to mildly impaired to GDM).
METHODS
This analysis was conducted within an ongoing prospective observational cohort study evaluating the relationship between glucose tolerance status in pregnancy and metabolic function in the years after delivery (11) . In this study, women are recruited into a pregnancy cohort at the time of antepartum screening for GDM and undergo metabolic characterization at recruitment and again at 3 mo and 1 yr postpartum. During the latter visit, they are recruited into the longterm cohort study in which participants undergo serial metabolic characterization every 2 yr thereafter. The protocols of the pregnancy cohort and the long-term cohort study have been approved by the Mount Sinai Hospital Research Ethics Board, and all women have provided written informed consent for their participation.
At our institution, women are screened for GDM by 50-g glucose challenge test (GCT) late in the 2nd trimester, followed by referral for diagnostic oral glucose tolerance test (OGTT) if the GCT is abnormal (Ն7.8 mmol/l). For the pregnancy cohort, women are recruited either before or after the GCT, and all participants undergo a 3-h, 100-g OGTT for determination of glucose tolerance status (regardless of the GCT) (11) . As described previously (11) , the recruitment of women following an abnormal GCT is a feature of the design that serves to enrich the study population for those with varying degrees of gestational dysglycemia. The resultant cohort thus reflects the full spectrum of glucose tolerance in pregnancy from normal [normal GCT with normal glucose tolerance (NGT) on the OGTT] to mildly abnormal (abnormal GCT with NGT) to gestational impaired glucose tolerance (GIGT) to GDM (11) . This study population thus reflects a gradient of future risk for prediabetes and diabetes (11, 16) .
Of the 440 women from the pregnancy cohort who were approached at 1 yr postpartum, 337 agreed to participate in the current study. As compared with the participants, the 103 women who declined showed no significant differences in age, ethnicity, family history of diabetes, glucose tolerance, or physical activity at 1 yr, although they had slightly lower BMI (median: 23.8 vs. 24.7 kg/m 2 , P ϭ 0.01). Seven participants had incomplete data on breastfeeding practices, yielding a study population of 330 women for the current analysis.
Assessment of lactation exposure. At each of the study visits at 3 mo, 1 yr, and 3 yr postpartum, participants completed intervieweradministered questionnaires, physical examination, and an OGTT, as described previously (11) . The duration of any breastfeeding and exclusive breastfeeding was determined from interviewer-administered questionnaires. Specifically, participants provided the timing of initiation of each of breastfeeding, formula, and solid foods and the timing of cessation of breastfeeding and formula. Exclusive breastfeeding was defined as infant feeding that consisted only of breastmilk with no formula or solids. As described previously (11) , physical activity in the preceding year was assessed at 3 yr postpartum using the Baecke Questionnaire.
Assessment of glucose metabolism outcomes. A 2-h, 75-g OGTT was performed at each of the study visits at 3 mo, 1 yr, and 3 yr postpartum, enabling determination of glucose tolerance status, insulin sensitivity/resistance, and ␤-cell function, as described previously (11) . All OGTTs were performed in the morning after overnight fast, with venous blood samples drawn for the measurement of glucose and specific insulin at fasting and at 30, 60, and 120 min. Specific insulin was measured with the Roche-Elecsys-1010 immunoassay analyzer and electrochemiluminescence immunoassay kit (Roche Diagnostics, Laval, QC, Canada).
Glucose tolerance status was defined on each OGTT according to Canadian Diabetes Association guidelines (3) . Dysglycemia refers collectively to prediabetes (impaired glucose tolerance, impaired fasting glucose, or both) and diabetes. Insulin sensitivity was measured on each OGTT with the Matsuda index, an established measure of whole body insulin sensitivity that has been validated against the euglycemic hyperinsulinemic clamp (12) . Insulin resistance was measured with homeostasis model of assessment of insulin resistance (HOMA-IR) (13) . ␤-Cell function was assessed on each OGTT with the Insulin Secretion Sensitivity Index-2 (ISSI-2), a validated measure of ␤-cell function that is analogous to the disposition index obtained from the intravenous glucose tolerance test (17, 18) . Insulinogenic index/HOMA-IR provided a second established measure of ␤-cell function (9) .
Statistical analyses. All analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC). The study population was stratified into three groups according to duration of lactation exposure at 1 yr postpartum: Յ3 mo, 3-12 mo, and Ն12 mo. Continuous variables were tested for normality of distribution, and natural log transformations of skewed variables were used, where necessary, in subsequent analyses. Univariate differences across the groups were assessed using analysis of variance or Kruskal-Wallis test for continuous variables and 2 test or Fisher exact test for categorical variables ( Table 1) .
Linear mixed-model analyses were performed to determine the predicted postpartum trajectories of insulin sensitivity and resistance (Matsuda index and HOMA-IR, respectively), ␤-cell function (ISSI-2, insulinogenic index/HOMA-IR), and glycemia (fasting and 2-h blood glucose) in each of the three lactation exposure groups after adjustment for age, ethnicity, family history of diabetes, prepregnancy BMI, and months since delivery ( Fig. 1 ). In the linear mixed model, we analyzed the repeated measured outcomes above, specifying random intercept and slope and assuming first-order autoregressive covariance structure (which was selected based on lowest Akaike information criterion). To compare average differences in the outcomes between the three groups over the duration of followup, we further constructed a series of linear mixed models as follows: model 1, adjusted for age, ethnicity, family history of diabetes, prepregnancy BMI, and months postpartum; model 2, which is model 1 further adjusted for GDM; and model 3, which is model 2 further adjusted for total physical activity at 3 yr ( Table 2) .
Logistic regression analyses ( Fig. 2 , panel A) were performed to determine whether the AAP recommendation of lactation for Ն12 mo predicts a lower likelihood of dysglycemia (prediabetes/diabetes) at 3 yr postpartum after adjustment for all of the covariates in the fully adjusted model 3 in Table 2 . A series of sensitivity analyses was conducted with further adjustment for either the measured value at 3 yr or the change between 3 mo and 3 yr postpartum in Matsuda index, waist circumference, and BMI, respectively.
Similarly, we stratified the population into three groups based on duration of exclusive breastfeeding (Ͻ3 mo, 3-6 mo, Ն6 mo) and then performed all of the linear mixed-model analyses ( Fig. 3 and Table 3 ) as before. We also evaluated whether the AAP recommendation of exclusive breastfeeding for Ն6 mo is associated with prediabetes/diabetes at 3 yr postpartum in logistic regression analysis ( Fig. 2, panel B ). Table 1 shows the characteristics of the study population at initial recruitment in pregnancy and at followup at 3 mo, 1 yr, and 3 yr postpartum stratified into the following three groups: women who breastfed for Յ3 mo (n ϭ 70), those who did so for 3-12 mo (n ϭ 140), and those who breastfed Ն12 mo (n ϭ 120). Prepregnancy BMI was highest in women who subsequently breastfed Յ3 mo (P ϭ 0.018). Otherwise, the groups E216 LACTATION AND DIABETIC RISK did not differ in age, ethnicity, family history of diabetes, or glucose tolerance status in pregnancy.
RESULTS
At 3 mo postpartum, the three groups differed significantly with respect to BMI, insulin sensitivity (Matsuda index), insu-lin resistance (HOMA-IR), and fasting glucose (all P Յ 0.0001). Notably, women with lactation Յ3 mo had higher BMI, lower insulin sensitivity, and higher fasting glucose than those in whom lactation was ongoing. At 1 yr postpartum, Table 1 . Characteristics at recruitment in pregnancy, 3 mo postpartum, 1 yr postpartum, and 3 yr postpartum of the following lactation exposure groups: women who breastfed for Յ3 mo, those who breastfed 3-12 mo, and those who breastfed Ն12 mo 
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LACTATION AND DIABETIC RISK these differences persisted for BMI (P ϭ 0.002), Matsuda index (P ϭ 0.036), and HOMA-IR (P ϭ 0.003) but were less pronounced, whereas fasting glucose no longer differed between the groups. At 3 yr postpartum, differences in BMI (P ϭ 0.01) and insulin sensitivity/resistance (Matsuda: P ϭ 0.014; HOMA-IR: P ϭ 0.067) were still present but again less pronounced. Importantly, however, glucose tolerance status now differed between the groups (P ϭ 0.028). Indeed, the prevalence of dysglycemia (prediabetes or diabetes) at 3 yr postpartum was lower in women with lactation Ն12 mo (12.5%) than in those who breastfed for Յ3 mo (21.4%) or for 3-12 mo (25.7%). Most of the dysglycemia was prediabetes, with prevalence rates of diabetes of 4.3, 3.6, and 0.8%, as duration of prior lactation increased from Յ3 to 3-12 to Ն12 mo, respectively.
Postpartum trajectories of insulin sensitivity/resistance, ␤-cell function, and glycemia. We next performed mixedmodel analyses to determine the predicted postpartum trajectories of insulin sensitivity/resistance, ␤-cell function, and glycemia in each of the lactation exposure groups after adjustment for age, ethnicity, family history of diabetes, prepregnancy BMI, and months since delivery (Fig. 1 ). As shown in Fig. 1A , Matsuda index decreased over 3 yr in all three groups but along different trajectories (P Ͻ 0.0001), reflecting ongoing greater insulin sensitivity in the women who breastfed for 3-12 and Ն12 mo. Similarly, these two groups showed lower insulin resistance (HOMA-IR; Fig. 1B ). There were no differences in ␤-cell function between the three groups (Fig. 1, C and  D) . However, fasting glucose differed significantly (P Ͻ 0.0001), remaining lower across the 3 yr in those who breastfed for 3-12 and Ն12 mo (Fig. 1E) . Finally, the three groups predicted distinct trajectories of 2-h blood glucose on the OGTT (P ϭ 0.029; Fig. 1F ). Whereas the differences in insulin sensitivity/resistance and fasting glucose reflected better metabolic function in both of the higher lactation exposure groups, there was a graded differential in 2-h glucose. Specifically, in contrast to the slight rise in 2-h glucose over time that was seen in the other two groups, women with lactation Ն12 mo showed no such increase, which may have contributed to their lower risk of prediabetes/diabetes at 3 yr postpartum.
Differences in insulin sensitivity/resistance, ␤-cell function, and glycemia. In a series of mixed models, we next evaluated the adjusted average differences in Matsuda index, HOMA-IR, ISSI-2, insulinogenic index/HOMA-IR, fasting glucose, and 2-h glucose between the groups over the duration of the followup ( Table 2) . Compared with women with lactation Յ3 mo (reference), both of the longer lactation exposure groups (3-12 and Ն12 mo) showed higher Matsuda index and lower HOMA-IR in all models, consistent with lesser worsening of insulin sensitivity/resistance. There were no differences be- 
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LACTATION AND DIABETIC RISK tween the groups in ␤-cell function. Mirroring the changes in insulin sensitivity/resistance, fasting glucose was significantly lower in women who lactated for 3-12 and Ն12 mo in all models. However, only those with lactation Ն12 mo exhibited significantly lower 2-h glucose, an effect that was ultimately attenuated to borderline significance in the fully adjusted model 3 (P ϭ 0.0725). These findings were unchanged in sensitivity analyses, adjusting for gestational glucose tolerance (instead of GDM) in model 2 for each outcome (data not shown). Similarly, adjustment for postpartum BMI also yielded largely unchanged findings (data not shown).
Predictors of prediabetes/diabetes at 3 yr postpartum. Having demonstrated that lactation for Ն12 mo predicts favorable patterns of lesser worsening of insulin sensitivity/resistance, fasting glucose, and 2-h glucose, we next sought to determine whether achievement of this AAP breastfeeding recommenda- 
E219
LACTATION AND DIABETIC RISK tion predicts better glucose tolerance at 3 yr. On logistic regression analysis (Fig. 2, panel A) , lactation for Ն12 mo indeed independently predicted a lower likelihood of prediabetes/diabetes at 3 yr postpartum (OR ϭ 0.37, 95% CI 0.18 -0.78, P ϭ 0.009). Of note is that whereas time since delivery, ethnicity, prepregnancy BMI, and GDM were all independent predictors of prediabetes/diabetes at 3 yr, lactation Ն12 mo emerged as a lifestyle behavior that can significantly reduce this risk. Furthermore, this finding was unchanged in a series of sensitivity analyses in which the logistic regression model in Fig. 2, panel A , was further adjusted for either the measured value at 3 yr postpartum or the change from 3 mo to 3 yr in 1) Matsuda index, 2) waist circumference, and (3) BMI, respectively (data not shown). Thus, the beneficial effect of lactation for Ն12 mo on glucose tolerance at 3 yr could not be fully reconciled by its effects on insulin sensitivity or anthropometry.
Duration of exclusive breastfeeding. Having demonstrated the sustained glycemic benefits of lactation for Ն12 mo, we next sought to address the impact of the other AAP recommendation of exclusive breastfeeding for 6 mo. Stratification of the study population based on duration of exclusive breastfeeding yielded 116 women who did so for Ͻ3 mo, 99 who breastfed exclusively for 3-6 mo, and 115 women who achieved the target of Ն6 mo. As shown in Fig. 3 , these three groups predicted distinct trajectories of the Matsuda index (Fig. 3A) , HOMA-IR ( Fig. 3B ), fasting glucose (Fig. 3E) , and 2-h glucose (Fig. 3F) , with exclusive breastfeeding for Ͻ3 mo yielding less favorable patterns for each outcome. Similarly, exclusive breastfeeding for Ն6 mo had beneficial effects on the adjusted average differences in Matsuda index, HOMA-IR, fasting glucose, and 2-h glucose over 3 yr (Table 3) , with only the latter association attenuated to borderline significance in the fully adjusted model. Finally, on logistic regression analysis (Fig. 2, panel B) , exclusive breastfeeding for Ն6 mo predicted a lower likelihood of prediabetes/diabetes at 3 yr postpartum at borderline significance (OR ϭ 0.49, 95% CI 0.24 -1.00, P ϭ 0.051).
DISCUSSION
In this study, we demonstrate that both lactation for Ն12 mo and exclusive breastfeeding Նfor 6 mo are associated with beneficial changes in the natural history of insulin sensitivity/ resistance (but not ␤-cell function) over the first 3 yr postpartum. This sustained enhancement of insulin sensitivity is accompanied by concomitant lowering of fasting glucose and postchallenge blood glucose. Indeed, lactation for Ն12 mo independently predicts a lower likelihood of prediabetes/diabetes at 3 yr postpartum. Thus, adherence to the AAP breast- Large epidemiological studies have noted that middle-aged women who report a longer duration of lactation during their earlier childbearing years have a lower long-term risk of T2DM (7, 20, 23, 25) . However, these retrospective associations may be confounded by 1) unmeasured risk factors affecting lactation or glucose metabolism and 2) misclassification of either exposure (i.e., recall of lactation that occurred many years earlier) or outcome (i.e., self-reported diabetes). These concerns are particularly relevant in the absence of a mechanistic basis for the association. Prospective studies have confirmed an inverse association between lactation and incident T2DM in the high-risk population of women with GDM but have not addressed the underlying mechanism (5, 27) . Accordingly, as repeatedly noted in the literature (7, 14, 15) , a critical gap has been the absence of direct biochemical evidence of postweaning effects on glucose metabolism that could link the established acute metabolic effects of lactation with modification of future risk of T2DM.
The few studies evaluating postweaning metabolic status have generally performed cross-sectional assessment without systematic ascertainment of glucose tolerance and its pathophysiological determinants (insulin sensitivity and ␤-cell function) (6, 8, 21) . In this regard, the current repeated longitudinal characterization of these features over 3 yr in women reflecting the complete spectrum of gestational glucose tolerance is revealing, enabling elucidation of the impact of lactation on the natural history of glucose metabolism. Indeed, whereas previous studies have shown that women typically experience a modest worsening of insulin resistance over the first 4 yr postpartum (11, 26) , we show that an insulin-sensitizing effect of lactation persists after weaning, thereby yielding a favorable shift in this natural history.
Three key points have emerged from our characterization of the trajectories of glucose metabolism. First, lactation appears to impact the natural history of insulin sensitivity/resistance but not ␤-cell function. Second, although the non-insulin-mediated uptake of glucose for lactogenesis by the mammary glands may contribute to the acute insulin-sensitizing effect of lactation (3), this mechanism cannot account for the persistent postweaning impact, suggesting the existence of other factors in modifying the trajectory of insulin sensitivity/resistance. Third, to understand the long-term metabolic impact of lactation, consideration of the natural history of glucose metabolism may be critical. Specifically, the cross-sectional comparisons each at 3 mo, 1 yr, and 3 yr postpartum (Table 1) suggest that the beneficial effects of longer duration of lactation on insulin sensitivity/resistance and fasting glucose may become less pronounced over time. However, the effect of lactation for Ն12 mo on fasting and 2-h glucose only yielded better glucose tolerance at 3 yr postpartum, when the natural history of modestly rising glycemia over time (particularly 2-h glucose) transformed the sustained postweaning glucose-lowering benefits of lactation into a reduced prevalence of prediabetes/ diabetes. Indeed, our mixed-model analysis suggests that, compared with lactation for Յ3 mo, breastfeeding for Ն12 mo should yield average reductions of 0.2 and 0.3 mmol/l in fasting and 2-h glucose, respectively, over the first 3 yr postpartum. Superimposed on the natural history of rising glycemia over time, these reductions should eventually yield a lower incidence of first prediabetes and then diabetes. The impact of lactation on the natural course of insulin sensitivity likely contributes to its sustained beneficial effect on fasting glucose. However, as shown in the logistic regression sensitivity analyses, the effects of lactation Ն12 mo on insulin sensitivity, waist, and BMI do not fully account for the reduced risk of prediabetes/diabetes at 3 yr. Similarly, in previous studies, BMI has not reconciled the effect of lactation on risk of T2DM (5, 23, 25, 27) . As such, other factors may be relevant. Prolactin has been associated with positive effects on ␤-cell physiology (19) , although our analyses show no significant lactation-induced changes in the natural history of ␤-cell function. Finally, prior lactation has been associated with higher serum ghrelin and peptide YY at 3 yr (22), raising the possibility of postweaning effects on appetite regulation that warrant further mechanistic evaluation.
Since randomization isn't feasible for clinical studies of lactation, a necessary limitation of this study is its observational design. Also, we demonstrate a reduced prevalence of prediabetes/diabetes at 3 yr rather than diabetes alone. This concession reflects the practical consideration that demonstration of a lactation-associated reduction in incident T2DM in the general population (i.e., not just GDM) would require an extremely large study with a very long followup. Instead, by designing this study specifically in women comprising the full spectrum of gestational glucose tolerance (reflecting a range of diabetic risk), it was possible to directly demonstrate a reduction in prediabetes/diabetes over 3 yr. In doing so, we show how lactation can induce postweaning effects on trajectories of glucose metabolism, thereby yielding mechanistic insight into its modification of diabetic risk that can reconcile the existing body of retrospective epidemiological associations between past lactation exposure and lower prevalence of T2DM in middle age.
Despite consistent recommendations of the AAP and other authoritative bodies (1, 4) , rates of breastfeeding remain suboptimal. In 2014, the Centers for Disease Control reported that only 26.7% of women breastfeed for 12 mo and that only 18.8% do so exclusively for 6 mo (4). Although infant nutrition has been the primary basis for existing guidelines, our study demonstrates that achievement of the recommended breastfeeding targets has persistent beneficial effects on maternal metabolism that can lower future diabetic risk. Accordingly, lactation is a modifiable postpartum behavior that can benefit both mother and child and may help to address the growing epidemic of diabetes in women.
In summary, lactation for Ն12 mo and exclusive breastfeeding for Ն6 mo are associated with favorable changes in the natural history of insulin sensitivity/resistance, fasting glucose, and postchallenge blood glucose. These lifestyle practices predict a lower likelihood of prediabetes/diabetes by 3 yr postpartum. Thus it emerges that adherence to the AAP breastfeeding recommendations provides sustained postweaning beneficial effects on insulin sensitivity/resistance that can reduce a woman's future risk of diabetes. 
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